The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review

Over recent years, the expanding evidence base for sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapies has revealed benefits beyond their glucose-lowering efficacy in the treatment of Type 2 diabetes mellitus (T2DM), resulting in their recognition as cardiorenal medicines. While SGLT2is cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilding, John P. H., Evans, Marc, Fernando, Kevin, Gorriz, Jose Luis, Cebrian, Ana, Diggle, Jane, Hicks, Debbie, James, June, Newland-Jones, Philip, Ali, Amar, Bain, Stephen, Da Porto, Andrea, Patel, Dipesh, Viljoen, Adie, Wheeler, David C., Del Prato, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934539/
https://www.ncbi.nlm.nih.gov/pubmed/35307801
http://dx.doi.org/10.1007/s13300-022-01228-w

Ejemplares similares

Ejemplares similares